Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2013

01-01-2013 | Letter To the Editor

Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer

Authors: Danila Coradini, Federico Ambrogi, Patrizia Boracchi

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Excerpt

To the Editor, …
Literature
1.
Spyratos F, Valet F, Bieche I, Scott V, Lehmann-Che J, Asselain B, Tembo O, Marty M, de Cremoux P (2012) Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat 134:443–448PubMedCrossRef
2.
Coradini D, Boracchi P, Ambrogi F, Biganzoli E, Oriana S (2012) Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ. Int J Surg Oncol. doi:10.​1155/​2012/​254085
3.
Coradini D, Ambrogi F, Oriana S, Biganzoli E, Boracchi P (2012) Differential expression of genes involved in cell polarity, EMT and cell-fate in breast cancer and corresponding normal tissue. Adv Breast Cancer Res 1:12–19
4.
Coradini D, Fornili M, Ambrogi F, Boracchi P, Biganzoli E (2012) TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J Biomed Biotechnol. doi:10.​1155/​2012/​984346
5.
Ferrari F, Bortoluzzi S, Coppe A, Sirota A, Safran M, Shmoish M, Ferrari S, Lancet D, Danieli GA, Bicciato S (2007) Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics 8:446PubMedCrossRef
1.
Coradini D, Ambrogi F, Boracchi P (2012) Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer
2.
Spyratos F, Valet F, Bieche I, Scott V, Lehmann-Che J, Asselain B, Tembo O, Marty M, de Cremoux P (2012) Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat 134:443–448PubMedCrossRef
3.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211PubMedCrossRef
4.
Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A (2010) Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat 120:567–579PubMedCrossRef
5.
Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC (2011) Jetset: selecting an optimal microarray probe set to represent a gene. BMC Bioinformatics 12:474PubMedCrossRef
6.
Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Bio 4:33–45CrossRef
Metadata
Title
Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer
Authors
Danila Coradini
Federico Ambrogi
Patrizia Boracchi
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2379-8

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue

Preclinical study

Vimentin DNA methylation predicts survival in breast cancer

Review

Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype

Clinical Trial

Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage

Clinical Trial

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

Preclinical Study

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes

Clinical trial

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits